Risk of Postoperative Hypermagnesemia in Cardiopulmonary Bypass Assisted Cardiovascular Surgery.
Autor: | Ghaddar M; Division of Nephrology, Department of Medicine, University of British Columbia, Canada., Hatab T; The Cleveland Clinic Foundation, OH, USA., El-Kaakour A; Division of Nephrology, Department of Medicine, University of Toronto, Canada., Tamim H; Clinical Research Institute and Department of Internal Medicine Faculty of Medicine, American University of Beirut, Lebanon.; College of Medicine, Alfaisal University, Riyadh, Saudi Arabia., Makki M; Clinical Research Institute and Department of Internal Medicine Faculty of Medicine, American University of Beirut, Lebanon., El-Halabi T; Department of Anesthesiology and Pain Medicine, American University of Beirut, Lebanon., Rifaii K; Division of Cardiothoracic Surgery, Department of Surgery, American University of Beirut, Lebanon., Sfeir P; Division of Cardiothoracic Surgery, Department of Surgery, American University of Beirut, Lebanon., Hoteit M; Division of Nephrology, Department of Medicine, American University of Beirut, Lebanon., Koubar SH; Division of Nephrology and Hypertension, Department of Internal Medicine, University of Minnesota, MN, USA. |
---|---|
Jazyk: | angličtina |
Zdroj: | Kidney360 [Kidney360] 2024 Oct 23. Date of Electronic Publication: 2024 Oct 23. |
DOI: | 10.34067/KID.0000000628 |
Abstrakt: | Background: Magnesium administration is a common practice in cardiovascular surgeries utilizing cardiopulmonary bypass (CPB). However, concerns persist regarding the risk of hypermagnesemia, particularly in patients with kidney dysfunction. This study aims to determine the incidence of postoperative hypermagnesemia in CPB-assisted cardiovascular surgeries and identify the associated risk factors. Methods: This was a retrospective cohort study conducted at a tertiary medical center. Data from adult patients undergoing open-heart surgery utilizing CPB between 2018 and 2020 were analyzed. Sociodemographic, perioperative, and clinical variables were collected from electronic medical records. Logistic regression was utilized to identify independent risk factors for hypermagnesemia. Results: Of 278 patients analyzed, 53.2% developed postoperative hypermagnesemia (Mg ≥2.5 mg/dL). Mild hypermagnesemia (Mg 2.5-3.9 mg/dL) was most common, with no significant impact on clinical outcomes observed. Patients with hypermagnesemia were older, with higher comorbidity burdens and lower baseline estimated glomerular filtration rate (eGFR). Cardioplegic solutions with higher magnesium content and lower baseline eGFR were independently associated with hypermagnesemia (OR 64.3; 95% CI 12.9-501.1 and OR 1.3; 95% CI, 1.1-1.5 respectively). Notably, ultrafiltration on CPB was associated with low risk of hypermagnesemia (OR 0.4, 95% CI 0.1-1.0, P value 0.048). Conclusions: This study highlights the importance of mindful magnesium supplementation strategies in those with advanced kidney disease. Future large-scale prospective multicenter studies should validate these findings and explore the extended effects of hypermagnesemia on clinical outcomes in patients with advanced CKD undergoing CPB surgeries. (Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Society of Nephrology.) |
Databáze: | MEDLINE |
Externí odkaz: |